Ivermectin does little to shorten recovery time from Covid, US clinical trial shows

Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Loading, please wait...
play article
Subscribers can listen to this article
pills generic
pills generic

The use of ivermectin to prevent Covid-19 hospitalisation has been disproved by a clinical trial conducted in the US. 

According to the findings, the anti-parasitic did not shorten the recovery period or prevent hospitalisation among a group of patients with mild-to-moderate Covid. 

The study was conducted by researchers at Duke University and Vanderbilt University and involved 1 500 participants, aged 30 years or older, who experienced two or more symptoms. About half of the participants received 400 mcg/kg of ivermectin for three days, while the others received a placebo (an inactive substance).

Read this for free
Get 14 days free to read all our investigative and in-depth journalism. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed.
Already a subscriber? Sign in